An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy
- 1 February 2001
- journal article
- case report
- Published by Wolters Kluwer Health in AIDS
- Vol. 15 (3) , 417-419
- https://doi.org/10.1097/00002030-200102160-00017
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus‐infected patients with chronic liver diseaseBritish Journal of Clinical Pharmacology, 2000
- Human Serum Attenuates the Activity of Protease Inhibitors toward Wild-Type and Mutant Human Immunodeficiency VirusVirology, 1998
- Low Plasma Concentrations of Indinavir are Related to Virological Treatment Failure in HIV-1-Infected Patients on Indinavir-Containing Triple TherapyAntiviral Therapy, 1998
- Pharmacokinetic Changes During Pregnancy and Their Clinical RelevanceClinical Pharmacokinetics, 1997